Key Takeaways:
Leerink Partners cut its price target on Eli Lilly and Co. (NYSE: LLY) by $238 to $1058, expressing concerns over the initial sales of the company’s new oral weight-loss drug, Foundayo, just days before its quarterly earnings report.
The downgrade reflects a "stark reality check" for the drug's U.S. launch, according to a recent Börse Global report. Foundayo secured only 3,700 prescriptions in its second week, falling far short of the 8,000 analysts expected and trailing the 18,400 scripts rival Novo Nordisk achieved in a similar post-launch window for its oral Wegovy pill.
The move from Leerink highlights a growing divide between analyst optimism and market reality. While roughly 83% of analysts rate the stock a Buy with an average price target of $1,225, shares have declined 18% year-to-date, closing Friday at €750 in Frankfurt and slipping below the stock's 200-day moving average.
The downgrade puts more pressure on management ahead of the company’s first-quarter results on April 30. Investors will be looking for reassurance that the Foundayo launch is a minor stumble and not a structural problem for a key part of Lilly's growth story.
Leerink is not the only firm sounding a note of caution. HSBC recently downgraded Eli Lilly to "Reduce" and slashed its price target to $850. The concerns come as competition in the lucrative weight-loss market intensifies, with Novo Nordisk's established treatments and new distribution channels emerging through telehealth platforms like Hims & Hers and Amazon's One Medical.
The price target reduction highlights investor sensitivity to execution in a market where expectations are sky-high. The company's April 30 earnings call will be a critical test of its ability to convince Wall Street that its ambitious growth trajectory remains intact.
This article is for informational purposes only and does not constitute investment advice.
